Myriad Genetics, Inc. (MYGN)
Nasdaq · Healthcare · Diagnostics & Research
$4.58+0.88%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $438M
- 52-week range
- $2.74 – $8.59
- 52-week change
- −43.18%
- EPS (trailing)
- −$1.18
- Analyst rating
- 3.2 Hold
- Next earnings
- Nov 2, 2026
Fiscal year to Dec 2025
- Revenue
- $825M (−1.56%)
- Net income
- −$366M
- Operating margin
- −47.0%
- Diluted EPS
- −$3.95
From the company’s annual report on SEC EDGAR.
About Myriad Genetics, Inc.
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.
Headquarters: Salt Lake City, United States · 2,700 employees · myriad.com